A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Medical experts reveal alarming risks as patients seek 'quick fix' weight loss injections without meeting clinical criteria, ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... and known heart disease backed by real-world ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

So, what's the tea on microdosing? It's pretty much what it sounds like — taking smaller doses than the usual prescribed ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

In 'Diet, Drugs, and Dopamine,' former FDA Commissioner David A. Kessler offers a comprehensive guide to weight loss.

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing cancer. A new study released Thursday suggests there’s a slightly ...